Role of ustekinumab in treatment of ulcerative colitis: a narrative review.

The therapeutic armamentarium for gastroenterologists in treating ulcerative colitis (UC) has been rapidly growing since the introduction of monoclonal antibodies directed against anti-TNFs. Ustekinumab is a monoclonal antibody binding the shared p40 subunit of IL-12 and IL-23, and the inhibition of these two cytokines, implicated in host response to microbial pathogens, has demonstrated clinical efficacy in different immune-mediated diseases, including moderate-to-severe UC. This narrative review summarizes the newest clinical evidence regarding the efficacy, effectiveness and safety of ustekinumab in moderate-to-severe UC, including specific situations (pregnancy, breastfeeding, elderly/pediatric populations, extraintestinal manifestations, acute severe UC, pouchitis and dual biological therapy). Finally, positioning is discussed in light of the existing evidence.

[1]  Sixi Zhang,et al.  Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review , 2023, Pediatric Drugs.

[2]  D. Laharie,et al.  Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies , 2023, United European gastroenterology journal.

[3]  A. Erden,et al.  Ustekinumab in enteropathic arthritis. , 2023, Immunotherapy.

[4]  J. Casanova,et al.  Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells , 2023, Cell reports.

[5]  C. Taxonera,et al.  Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis , 2023, Alimentary pharmacology & therapeutics.

[6]  C. Ooi,et al.  Accelerated ustekinumab dosing as rescue therapy in acute severe ulcerative colitis. , 2022, Journal of Gastrointestinal and Liver Diseases.

[7]  A. Ananthakrishnan,et al.  Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study , 2022, Journal of clinical medicine.

[8]  U. Kopylov,et al.  Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study , 2022, Alimentary pharmacology & therapeutics.

[9]  M. Toruner,et al.  European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. , 2022, Journal of Crohn's & colitis.

[10]  J. Gisbert,et al.  Efectiveness And Safety Of Ustekinumab In Elderly Patients With Crohn's Disease: Real World Evidence From The Eneida Registry. , 2022, Journal of Crohn's & colitis.

[11]  J. Allegretti,et al.  Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases. , 2022, Inflammatory bowel diseases.

[12]  J. Ludvigsson,et al.  Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register , 2022, United European gastroenterology journal.

[13]  B. Abraham,et al.  Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis , 2022, Crohn's & colitis 360.

[14]  M. Lukáš,et al.  Safety of ustekinumab and vedolizumab during pregnancy - pregnancy, neonatal and infant outcome: a prospective multicenter study. , 2022, Journal of Crohn's & colitis.

[15]  W. Fries,et al.  Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? , 2022, Drugs & Aging.

[16]  C. J. van der Woude,et al.  Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database , 2022, Alimentary pharmacology & therapeutics.

[17]  S. Vermeire,et al.  Real-world endoscopic and histologic outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis. , 2022, Journal of Crohn's & colitis.

[18]  M. Samaan,et al.  Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study , 2022, Frontline Gastroenterology.

[19]  I. Melero,et al.  Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, Pharmacology & therapeutics.

[20]  J. Kierkuś,et al.  Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature , 2022, Journal of clinical medicine.

[21]  B. Sands,et al.  Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension , 2022, Journal of Crohn's & colitis.

[22]  S. Bonovas,et al.  Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  E. Loftus,et al.  Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease , 2022, Crohn's & colitis 360.

[24]  M. Iborra,et al.  P383 Ustekinumab as an opportunity for refractory Ulcerative Colitis patients , 2022, Journal of Crohn's and Colitis.

[25]  J. Gisbert,et al.  ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. , 2021, Journal of Crohn's & colitis.

[26]  A. Alibrandi,et al.  One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy , 2021, Expert opinion on biological therapy.

[27]  A. Amiot,et al.  Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study , 2021, Alimentary pharmacology & therapeutics.

[28]  M. Bulajic,et al.  Is Ustekinumab Effective in Refractory Crohn’s Disease of the Pouch and Chronic Pouchitis? A Systematic Review , 2021, Digestive Diseases and Sciences.

[29]  J. Marshall,et al.  The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies , 2021, United European gastroenterology journal.

[30]  B. Strober,et al.  Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR , 2021, Drug Safety.

[31]  J. Allegretti,et al.  Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. , 2021, Inflammatory bowel diseases.

[32]  D. Rubin,et al.  Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis , 2021, ACG case reports journal.

[33]  A. Griffiths,et al.  One‐year outcomes with ustekinumab therapy in infliximab‐refractory paediatric ulcerative colitis: a multicentre prospective study , 2021, Alimentary pharmacology & therapeutics.

[34]  J. Gisbert,et al.  Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry , 2021, Journal of Crohn's & colitis.

[35]  E. Barnes,et al.  Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  M. Toruner,et al.  ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. , 2021, Journal of Crohn's & colitis.

[37]  Michael P. Jones,et al.  Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2021, Digestive Diseases and Sciences.

[38]  J. Smogorzewski,et al.  Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases , 2021, Dermatologic therapy.

[39]  D. Rubin,et al.  Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States , 2021, Crohn's & colitis 360.

[40]  J. Gisbert,et al.  The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU , 2021, Therapeutic advances in gastroenterology.

[41]  L. Peyrin-Biroulet,et al.  Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. , 2020, Journal of Crohn's & colitis.

[42]  A. Magnano,et al.  Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) , 2020, Expert opinion on biological therapy.

[43]  R. Weersma,et al.  Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study , 2020, Alimentary pharmacology & therapeutics.

[44]  D. Loeuille,et al.  Paradoxical gastrointestinal effects of interleukin-17 blockers , 2020, Annals of the Rheumatic Diseases.

[45]  P. Gionchetti,et al.  Ustekinumab for treating ulcerative colitis: an expert opinion , 2020, Expert opinion on biological therapy.

[46]  J. Gisbert,et al.  Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review , 2020, Drugs.

[47]  A. Amiot,et al.  Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study , 2020, Alimentary pharmacology & therapeutics.

[48]  A. Ruyssen-Witrand,et al.  Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis , 2020, RMD Open.

[49]  S. Janelidze,et al.  Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis , 2020, United European gastroenterology journal.

[50]  M. Murad,et al.  First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. , 2020, Clinical Gastroenterology and Hepatology.

[51]  B. Sands,et al.  Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[52]  L. Peyrin-Biroulet,et al.  Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks. , 2019, Inflammatory bowel diseases.

[53]  D. Franchimont,et al.  Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study. , 2019, Journal of Crohn's & colitis.

[54]  E. Savarino,et al.  Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[55]  D. D. de Jong,et al.  Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study , 2019, Journal of Crohn's & colitis.

[56]  N. Hyman,et al.  Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis , 2019, Digestive Diseases and Sciences.

[57]  S. Vavricka,et al.  Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series. , 2019, Journal of Crohn's & colitis.

[58]  D. Heijde,et al.  Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis , 2018, Arthritis & rheumatology.

[59]  H. Tilg,et al.  IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting , 2018, Nature Reviews Gastroenterology & Hepatology.

[60]  A. Stallmach,et al.  Ustekinumab Rescue Therapy in a Patient With Chronic Refractory Pouchitis. , 2018, Journal of Crohn's & colitis.

[61]  M. Allez,et al.  Successful Treatment With Ustekinumab for Chronic Refractory Pouchitis. , 2017, Journal of Crohn's & colitis.

[62]  C. Langner,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.

[63]  B. Stockinger,et al.  The dichotomous nature of T helper 17 cells , 2017, Nature Reviews Immunology.

[64]  T. Mcclanahan,et al.  Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. , 2015, Immunity.

[65]  J. McElwee,et al.  IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases , 2015, Nature Medicine.

[66]  Xiuqin Cheng,et al.  Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease , 2014, Inflammation Research.

[67]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[68]  A. Nikkels,et al.  Ustekinumab and Herpes Zoster , 2011, Dermatology.

[69]  M. Veldhoen,et al.  Fate mapping of interleukin 17-producing T cells in inflammatory responses , 2011, Nature Immunology.

[70]  T. Yoshimoto,et al.  Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27 , 2010, Clinical & developmental immunology.

[71]  C. Elson,et al.  Late developmental plasticity in the T helper 17 lineage. , 2009, Immunity.

[72]  Alastair Forbes,et al.  Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease , 2008, Nature Genetics.

[73]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[74]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[75]  R. D. Hatton,et al.  Transforming growth factor-β induces development of the TH17 lineage , 2006, Nature.

[76]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[77]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[78]  T. Mcclanahan,et al.  A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.

[79]  R. Rees,et al.  Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL- 12 , 1995, The Journal of experimental medicine.

[80]  S. Clark,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[81]  OUP accepted manuscript , 2022, Journal of Crohn’s and Colitis.